HER2 Targeting Therapies Market Assessment 2021-2030 with Profiles of

Dublin, Sept. 29, 2021 (GLOBE NEWSWIRE) — The “HER2 Targeting Therapies Market by Target Disease Indication, Type of Molecule, Type of Therapy and Route of Administration, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for HER2 targeting therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption rates and likely selling price of HER2 targeting therapies, we have provided informed estimates on the evolution of the market for the period 2021-2031.

The report also features the likely distribution of the current and forecasted opportunity across:

• [A] different target indications (breast cancer, gastric cancer head and neck cancer and lung cancer),

• [B] type of molecule (small molecule and biologic),

• [C] type of therapy (monotherapy, combination therapy and both),

• [D] route of administration (intravenous and oral) and,

• [E] key geographical regions (US, Europe, Asia-Pacific, Middle East and North Africa and Latin America).

To account for the future uncertainties and to add robustness to the model, the analyst has provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Historic Market Analysis and Current Trends

Human epidermal growth factor receptor 2 (HER2), a member of human epidermal growth factor receptor family, plays an important role in the development and progression of various types of cancers, especially breast cancer. Over time, it has been found to be an important target for the drug therapies intended for treating various types of breast cancer.

Story continues

HER2 targeting therapies have shown to be a promising treatment option, capable of preventing tumor cells from evading immune surveillance. In 1998, the FDA approved the first HER2 targeting monoclonal antibody, called Herceptin (trastuzumab) for the treatment of metastatic breast cancer. Later, in 2006, the drug got approved for HER2 positive early breast cancer. Following its success in treating breast cancer, significant efforts were made to evaluate its potential in other conditions involving HER2 alterations, such as overexpression, amplifications and other mutations.

Eventually in 2010, the drug got FDA approval for HER2 positive metastatic stomach cancer as well. In addition to Herceptin, more than five drugs have been approved and about 70 candidates are under development for breast cancer, HER2-positive biliary tract, colorectal, non-small-cell lung and gastric cancers….